Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Current and future therapies for treating chronic spontaneous urticaria
|Filename||105. Maurer et al., Current and future ther. CSU,ExpOpPharm2016.pdf|
|Date added||June 23, 2020|
|Tags||Alternative drugs, antihistamines, chronic spontaneous urticaria, ciclosporin, montelukast, omalizumab|
|Authors||Maurer, M., Vena, G. A., Cassano, N., and Zuberbier, T.|
|Citation||Maurer, M., Vena, G. A., Cassano, N., and Zuberbier, T.: Current and future therapies for treating chronic spontaneous urticaria. Expert Opin. Pharmacother. 2016: 17; 1131-1139.|
|Corresponding authors||Vena, G. A.|
|Edition; Page||17; 1131-1139.|
|Publisher||Expert Opin. Pharmacother.|
Introduction: Chronic spontaneous urticaria (CSU) is a disabling condition that causes deterioration of quality of life.
Areas covered: The international EAACI/GA2LEN/EDF/WAO guidelines have provided a stepwise treat- ment algorithm for CSU management. Second-generation H1-antihistamines are the first-line treatment, and the second step is the up-dosing of the same drugs. In refractory patients, the guidelines recommend the addition of omalizumab, ciclosporin A or montelukast. Systemic corticosteroids can be used as a short course during acute exacerbations. A plethora of alternative treatments has been evaluated, although the overall level of evidence for such treatments is low. Future treatment options may include inhibitors of skin mast cells and antagonists to mast cell-activating signals that are relevant for the induction of CSU signs and symptoms.
Expert opinion: The only licensed options included in the guidelines algorithm are standard-dosed second-generation H1-antihistamines and omalizumab. High-quality evidence has documented a rapid and strong symptomatic effect of omalizumab in CSU, although the optimal long-term regimens should be further investigated. The role of alternative drugs deserves additional studies. The potential of the existing treatments for inducing remission of CSU is unknown, and this is an important area of research, as is the evaluation of predictors of response, prognostic factors, and pathomechanisms.
(Last update: 08.2021)
|Number of publications (original work and reviews) in peer-reviewed journals:||636|
|Number of original publications in peer-reviewed journals:||462|
|Number of reviews in peer-reviewed journals:||174|
|Cumulative IF of publications (original work & reviews) in peer-reviewed journals:||3834,12|
|Cumulative IF for original publications in peer-reviewed journals:||3043,14|
|Cumulative IF for reviews in peer-reviewed journals:||790,98|
|Citations, Hirsch index: (view on Web of Science)||26429|